Introduction
Interleukin-2 receptor alpha (IL-2Ra) antagonists may be useful in treating graft-versus-host disease (GVHD), as GVHD is a T-cell autoreactive disorder 1 and IL-2Ra antagonists downregulate T cells. Daclizumab is a humanized monoclonal antibody to IL-2Ra. 2 Daclizumab has been shown to be safe in children when used to prevent rejection after solid organ transplantation. 3, 4 A few small studies have shown daclizumab to be effective in treating refractory acute and chronic GVHD in adults. 2, [5] [6] [7] Three of these studies included a small number of children; 2, 6, 7 however, results were not stratified by age. Thus, no conclusions can be drawn with regard to safety and efficacy of daclizumab for refractory GVHD in pediatrics.
We performed a retrospective review of 14 patients treated with daclizumab after hematopoietic stem cell transplant (HSCT) for GVHD at the Children's Hospital of Philadelphia to attempt to better characterize the efficacy and toxicity of this agent in children.
Materials and methods

Patients and dosing schedule
We identified 14 patients who were treated during the period of 2002-2005 with daclizumab for GVHD. This research protocol was reviewed and approved by the IRB and all patients who received daclizumab were included in this study, regardless of age, gender, disease, or GVHD type. Treatment plan consisted of a 12-week course of daclizumab. Dosing was 2 mg/kg weekly for the first 8 weeks followed by 1 mg/kg weekly for the remaining 4 weeks. Patients received daclizumab as outpatients in a closely monitored setting unless they were otherwise hospitalized. The dose was administered intravenously (i.v.) over 15-30 min.
Measurement of outcome
In order to have a consistent objective measurement of response to daclizumab, we defined response parameters described in Table 1 for this study. Our primary measurements of response were improvement or resolution of GVHD and ability to wean the steroid dose after initiation of a course of daclizumab.
Results
Patient characteristics
Clinical features of the 14 patients are shown in Table 2 . In all, 10 patients were treated with daclizumab for acute GVHD, three patients for chronic GVHD, and one patient was treated twice for acute and subsequently chronic GVHD. Daclizumab was used for five patients who had progression of GVHD after treatment, with at least a 6 day course of corticosteroids (2 mg/kg/day methylprednisone). In addition, it was used for one patient with rapid progression of GVHD despite steroids, and for eight patients who initially responded to corticosteroids, and subsequently had a GVHD flare while on corticosteroids.
The median time to the development of acute GVHD was 14 days (range, from 10 to 40). All patients in this series developed acute GVHD, and all patients were treated with i.v. methylprednisone at 1-2 mg/kg/day as the first line of therapy upon development of GVHD.
Response to daclizumab for acute GVHD Prior to beginning daclizumab therapy, four patients had cyclosporine converted to tacrolimus without improvement, and four patients had mycophenolate mofetil (MMF) added. Of these four patients, two had no improvement with MMF, one had MMF added at the same time as daclizumab confounding the results, and one patient had responded to MMF in the gut and liver, but not in the skin. Table 3 summarizes the features and responses of 11 patients treated for acute GVHD. The median time to addition of daclizumab after initiation of steroid therapy Table 1 Response criteria
Name Description
Complete response (CR) Resolution of all signs and symptoms of GVHD and a greater than 50% dose reduction of corticosteroids by 2 months from the initiation of daclizumab. Partial response (PR) Improvement in GVHD in one or more organs without progression in others and a greater than 50% dose reduction in corticosteroids by 2 months from the initiation of daclizumab. No response (NR) No change in GVHD or progression of GVHD with inability to wean corticosteroids by 2 months postinitiation of daclizumab.
Improvement is defined as having the equivalent of a two-grade decrease in GVHD. For example, a decrease from grade IV to grade II or grade III to grade I. Skin GVHD significantly improved in seven of the 10 patients with skin involvement, including five patients with a CR and two with a PR. Of these seven patients, corticosteroids were weaned over 50% of the predaclizumab dose, and all of these patients were able to have corticosteroids reduced within 2 weeks after starting therapy. All seven of these patients completed the 12-week course. Only one patient who completed the 12-week daclizumab course did not have a marked response. This patient had improvement in skin GVHD with daclizumab; however, the response lasted for less than 1 week. This patient was classified as a non-responder.
Five of these 10 patients are alive and two are alive and off all immunosuppressive medications. Four of those who responded to daclizumab and are alive had recurrent GVHD at 2, 4, 5, and 6 months after completion of the 12-week daclizumab course. All of these patients initially had severe acute GVHD (grade III or IV skin) and were refractory to corticosteroids and calcineurin inhibitors. After recurrence, the GVHD was less severe chronic GVHD (o25% body surface) and was no longer refractory to corticosteroids and calcineurin inhibitors. Thus, while these patients recurred and required further treatment, their GVHD was less severe and more easily manageable. One of these four patients was eventually weaned off immunosuppressive medications after recurrence. Two patients who initially responded to daclizumab died after completing the daclizumab course but neither died from GVHD or a side effect attributable to daclizumab.
One patient with acute GVHD localized to gut was not evaluable. Octreotide was added at the same time as daclizumab, and both rotavirus and Clostridium difficile gastroenteritis were eventually isolated which responded to antibiotic therapy. This patient died of relapsed AML.
Response to daclizumab for chronic GVHD Four patients were treated with daclizumab for chronic GVHD and Table 4 summarizes their responses. Three patients completed the 12 doses and the fourth had daclizumab stopped after five doses with no response. One patient had a CR but eventually recurred and required reinitiation of steroids. Upon recurrence, this patient had less severe GVHD and was no longer corticosteroid refractory. One patient had both skin and liver GVHD. This patient was treated with daclizumab and had a PR with resolution of skin GVHD but no effect of liver GVHD. After 3 months, the skin GVHD recurred and the patient was retreated with daclizumab and had a CR. This patient is no longer on immunosuppressive medications.
Course of treatment, toxicity, and outcomes
No patients had any side effects or appreciable delayed effects from daclizumab infusion. Six of 14 patients in this cohort died (Table 5) . Daclizumab was not thought to be This patient was treated with two courses of daclizumab and had a complete resolution of skin GVHD with both courses; however, daclizumab had no effect on liver GVHD with the first course. Daclizumab for Children with GVHD DT Teachey et al causative in the relapse or deaths of any of these patients. Two patients died from disease relapse, including one patient who died of relapsed AML during daclizumab treatment and one patient who relapsed 1 month after completing daclizumab and died 2 months later. Three deaths were from infection. One patient died from antecedent infection 72 h after receiving the drug and a second died from ARDS 27 days after a single dose. The third patient died of complications of CMV 15 months after HSCT and 14 months after receiving daclizumab. It is unlikely based on the timing and dosing of daclizumab that it contributed to these deaths. Only one patient died from progressive GVHD and that patient only received one dose of daclizumab.
Discussion
Daclizumab is a humanized monoclonal IgG1, which recognizes the 55-kDa alpha chain of IL-2Ra. 2 IL-2R is expressed only on activated T cells and blockage of IL-2R results in decreased T-cell activation and proliferation. GVHD is a T-cell autoreactive disorder, 1 and by downregulating T cells, IL-2R antagonists could be useful in treating GVHD. The ability of daclizumab to downregulate T-cell activity has been shown extensively in patients who received solid organ transplantation. 3, 4, 8 Daclizumab has been shown to be effective and well tolerated when used to prevent rejection after kidney, 3 liver, 4 heart, 8 and intestinal transplant. 9 Studies using daclizumab for acute GVHD are limited. The few small series in adults with steroid refractory acute GVHD have demonstrated response rates of 29-47%. 2, 5, 6, 10 Experience using daclizumab for chronic GVHD is available in only one small series. 5 The few series which evaluated efficacy of daclizumab for refractory GVHD and included a small number children did not stratify results based on age, leaving the data inevaluable for children. 2, 6, 7 As with patients who received solid organ transplants, few adverse effects have been noted in patients who received daclizumab for treatment of GVHD. Development of post-transplant EBV lymphoproliferative disease 2 and hypersensitivity reactions 11 have been reported, but no patient in our cohort was noted to have these or any side effect after treatment with daclizumab. Treatment with daclizumab carries a theoretical risk of infection and secondary malignancy; 12 however, no patient in our series developed either after initiating treatment.
A theoretical risk of daclizumab is amelioration of GVL and increased relapse. Recently, a study randomizing patients to corticosteroids or corticosteroids and daclizumab for GVHD prophylaxis showed worse survival in the group receiving corticosteroids and daclizumab. 13 One half of the deaths in the daclizumab arm in this series were disease related. It is important to emphasize that in this study, the drug was used for de novo treatment of GVHD, not for refractory GVHD. No published study has demonstrated an increased relapse rate or mortality in patients who received daclizumab for treatment of refractory GVHD. Adding additional immunosuppressive agents to any regimen will not be without some risk. Thus, treating every patient with acute GVHD with additional immunosuppressive agents in addition to corticosteroids at the onset of GVHD is probably not justified. In our series, two patients relapsed while receiving, or shortly after receiving, daclizumab. Both patients were at high risk for relapse; one was a primary induction failure with AML who relapsed while receiving daclizumab course, and the second had a history of an early relapse of T-ALL.
The optimal dose and schedule of daclizumab in patients who received a HSCT is unknown. While pharmacokinetic studies have been performed in children using daclizumab after solid organ transplantation, 14 these data do not necessarily apply to patients who have received HSCT due to their hypermetabolic state. We used a novel regimen of daclizumab in our series and found satisfactory results.
In this series of patients, daclizumab demonstrated efficacy in patients with acute and chronic refractory skin GVHD. In many patients these responses were not durable, however, the majority of patients who responded and later recurred had less severe and easier to treat GVHD. We had insufficient numbers of patients with other GVHD manifestations to evaluate its efficacy beyond skin. Our series found daclizumab to be relatively safe in these patients. Larger studies using daclizumab with pharmokinetic data assessment are needed to determine the role of this agent in the management of GVHD.
